0
Cardiothoracic Surgery |

The Impact of Microscopically Positive Final Pathologic Margins Identified Days After Surgery in Resected Non-small Cell Lung Cancer (NSCLC)

David Odell, MD; Joseph Wizorek, MD; Matthew Schuchert, MD; Kristen McCormick, BS; David Wilson, MD; Jill Siegfried, PhD; James Luketich, MD; Rodney Landreneau, MD
Author and Funding Information

University of Pittsburgh, Pittsburgh, PA


Chest. 2013;144(4_MeetingAbstracts):116A. doi:10.1378/chest.1702017
Text Size: A A A
Published online

Abstract

SESSION TITLE: Unusual Problems and Thoracic Surgical Solutions

SESSION TYPE: Original Investigation Slide

PRESENTED ON: Tuesday, October 29, 2013 at 04:30 PM - 05:30 PM

PURPOSE: Complete (R0) anatomic resection affords the best opportunity for cure in patients with resectable NSCLC. Some tumors exhibit more aggressive tumor biology, resulting in encroachment on bronchial and vascular surgical margins of resection. Margin involvement determined only on final pathologic analysis several days after surgery poses a particular management dilemma. We evaluate the impact on recurrence and survival of microscopically positive surgical margins found on final pathology in resected NSCLC.

METHODS: Retrospective review of 2,466 patients undergoing anatomic lung resection for NSCLC from 1998-2012 to identify all patients with microscopically positive resection margins noted only on final pathology. A matched cohort of patients with negative margins was identified accounting for age, gender, tumor size, tumor location, clinical stage, use of induction therapy and operation performed. Primary outcomes were incidence and patterns of recurrence. Kaplan-Meier actuarial freedom from recurrence and overall survival estimates were performed.

RESULTS: Microscopically positive final pathologic margins were identified in 63 patients (2.6%) - lobectomy=42 (66.7%), bi-lobectomy=4(6.3%), sleeve resection=7(11.1%), pneumonectomy=10(15.9%). The median age was 67.2y (range: 35-87), mean tumor size was 4.8 ± 2.4cm. 76.1% stage 2B or above. 44.4% were adenocarcinoma and 41.3% squamous carcinoma. Involved margins were bronchial (n=39, 61.9%), vascular (n=20, 31.7%), parenchymal (n=6, 9.5%) or peribronchial/perivascular (n=5, 7.9%). 15 patients (23.8%) received neoadjuvant therapy and 52 (82.5%) adjuvant therapy. Margin positive patients had significantly increased rates of pathologic upstaging (66.7% vs 30.2%, p=0.0001) and use of adjuvant therapy (82.5% vs 41.3%, p=0.0001). No significant difference was noted in the patterns of recurrence between groups. Despite more aggressive therapy, patients with positive margins had significantly worse median (36 vs 19 months) and five year (37% vs 12%, p=0.009) overall survival.

CONCLUSIONS: Microscopically positive surgical margins (R1) on final pathology are associated with increased rates of pathological upstaging and a worse overall survival. This finding portends aggressive disease biology and a poor prognosis irrespective of treatment strategy.

CLINICAL IMPLICATIONS: Positive final pathologic margin appears to be a harbinger of advanced disease rather than a by-product of inadequate surgical therapy. Aggressive surgical re-resection may not be warranted in these patients.

DISCLOSURE: The following authors have nothing to disclose: David Odell, Joseph Wizorek, Matthew Schuchert, Kristen McCormick, David Wilson, Jill Siegfried, James Luketich, Rodney Landreneau

No Product/Research Disclosure Information


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
Non-small Cell Lung Cancer*: Role of Surgery for Stages I-III
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543